Doxazosin Tablet
Product Images NDC 16729-414

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 16729-414). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Accord Healthcare Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 mg : 100 Tablets (Doxazosin 1mg 100)

Label for Doxazosin Tablets USP, 1 mg strength, produced by Accord Healthcare Inc. The label includes dosage and storage instructions, manufacturer information, and a quantity of 100 tablets. The label also has multiple barcodes, an NDC number 16729-211-01, and prescribing details such as Rx only and dispensing instructions for pharmacists.*

FDA Label Image

2 mg : 100 Tablets (Doxazosin 2mg 100)

Label for Doxazosin 2 mg tablets USP, oral prescription tablets. The label indicates 100 tablets per container, manufactured for Accord Healthcare Inc. It includes NDC 16729-414-01 and instructions for storage and dispensing. The label displays dosage strength and branding with Accord Healthcare name and logo.*

FDA Label Image

4 mg : 100 Tablets (Doxazosin 4mg 100)

Doxazosin Tablets USP 4 mg oral tablets label from Accord Healthcare Inc. The label indicates each tablet contains Doxazosin Mesylate USP equivalent to 4 mg Doxazosin, with 100 tablets per container. Manufacturer information includes Intas Pharmaceuticals Limited, Ahmedabad, India. Storage instructions and dispensing guidance are also visible.*

FDA Label Image

8 mg : 100 Tablets (Doxazosin 8mg 100)

Doxazosin Tablets USP 8 mg oral tablet label showing a 100 tablet count bottle. The label includes storage instructions, dosage form, strength, NDC 16729-415-01, and manufacturer details: Accord Healthcare Inc. and Intas Pharmaceuticals Limited. Marked Rx Only with a note to dispense with patient information leaflet.*

FDA Label Image

Table 1 (Doxazosin Fig1)

A data table titled 'Summary of Effectiveness Data in Placebo Controlled Trials' presenting results from three studies on Doxazosin. It includes symptom score and maximum flow rate mean baseline and mean change values for placebo and Doxazosin at various doses (4 mg, 8 mg, and up to 8 mg). Accompanying the table is a bar graph illustrating symptom score and maximum flow rate changes in Study 2 comparing placebo, 4 mg, and 8 mg doses.*

FDA Label Image

Figure 1 – Study 1 (Doxazosin Fig2)

Two line graphs depicting clinical trial results for Doxazosin treatment over 14 weeks. The left graph shows mean change in total symptom score from baseline comparing Doxazosin and placebo groups. The right graph shows mean increase in maximum urinary flow rate (mL/sec) from baseline for the same groups. Both graphs indicate greater improvement with Doxazosin, titrated to a maximum of 8 mg, compared to placebo.*

FDA Label Image

Chemical Structure (Doxazosin Str)

Chemical structure of Doxazosin, shown as a detailed molecular diagram including its component rings, atoms, and functional groups, along with a methanesulfonic acid (CH3SO3H) moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.